Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma) header
Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma) profile picture

We are a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy.

Joined October 2023
Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)Photo by Shuttle Pharmaceuticals (Nasdaq: SHPH) (@shuttlepharma)
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Our fireside chat at the @LythamIR 2025 Investor Healthcare Summit is now available for replay on YouTube. Watch now: youtu.be/uaLgzKW8mRU?si=vN9a… $SHPH
2
1
94
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Today we announced that we reached a key milestone in our Phase 2 Clinical Trial of Ropidoxuridine for the treatment of glioblastoma by achieving 25% enrollment in the trial’s initial randomized portion. View press release for more details: shuttlepharma.com/shuttle-ph… $SHPH
1
1
153
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
We are excited to partner with @UVACancerCenter as a trial site for our Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA Cancer Center is one of six cancer centers conducting the clinical trials. $SHPH
1
59
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
We are excited to collaborate with Georgetown University Medical Center as a trial site for our phase 2 clinical trial of ropidoxuridine for the treatment of patients with glioblastoma. Georgetown is one of six cancer centers conducting the clinical trial. $SHPH
1
1
120
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Today we announced a sponsored research agreement with the University of California, San Francisco (@UCSF) to advance pre-clinical development of our ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers. Read more: shuttlepharma.com/shuttle-ph… $SHPH
2
3
135
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Our CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on Monday, January 13, 2025, at 3:30 p.m. ET. Dr. Dritschilo will discuss the Company’s plans for 2025. Webcast registration: lythampartners.com/health202… Read press release: shuttlepharma.com/shuttle-ph… $SHPH
2
2
107
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Dr. Brown is a distinguished leader in drug discovery and translational medicine with over three decades of experience. Dr. Brown is a co-founder of our company, previously served as our Chief Scientific Officer for Chemistry, and has served as a member of our board of directors since the Company’s formation. Learn more about our leadership team: shuttlepharma.com/board-of-d… $SHPH
2
1
118
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
At Shuttle Pharma, we are pioneering innovative therapies that target cancer cells, protect healthy tissue, and harness the body’s innate immune response. Our mission is to enhance the power of radiation therapy while minimizing its side effects. Learn more at: shuttlepharma.com/ $SHPH
1
230
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
Today we announced first patient enrollment and dosing at the @UVACancerCenter in our Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat glioblastoma, a deadly malignancy of the brain with no known cure. Read more: globenewswire.com/news-relea… $SHPH
1
2
71
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
We recently provided a corporate update on our third quarter activities including the successful dosing of the first three patients in our Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma and finalizing agreements with all six planned enrollment locations for our Phase 2 clinical trial. Read more: shuttlepharma.com/shuttle-ph… $SHPH
2
1
129
Shuttle Pharmaceuticals (Nasdaq: SHPH) retweeted
We are excited to partner with Allegheny Health Network (AHN) Cancer Institute as a trial site for our Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Allegheny is one of six cancer centers conducting the clinical trials. We look forward to the continued advancement of the trial as we look to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. $SHPH
1
74